Efficacy of Centanafadine SR as a Potential Smoking Cessation Treatment
Status:
Recruiting
Trial end date:
2022-10-10
Target enrollment:
Participant gender:
Summary
This study will explore the efficacy and tolerability of centanafadine at a dose of 400 mg
per day of centanafadine in promoting smoking abstinence in adult smokers seeking to quit.
Phase:
Phase 2
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.